Post Marketing Surveillance And Special Surveillance for Mirapex® Tablet in Patients With Idiopathic Parkinson's Disease

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The objectives of this study are to investigate issues or questions about MIRAPEX Tablets as shown below through the Post Marketing Surveillance (PMS) study upon approval.

• Unexpected adverse events (especially, serious adverse events (SAEs))

• To find out the status of incidence of adverse events under actual practice

• Factors on the safety profile

• Factors on the efficacy profile

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Boehringer Ingelheim
• Treatments: Pramipexole

Criteria

Inclusion Criteria:

• Among the patients with idiopathic Parkinson's disease, from those receiving MIRAPEX Tablets first after a contract of the study to the requested number of cases will be consecutively enrolled without skipping

Exclusion Criteria:

• Following patients are contraindicated.

1. Patients who are hypersensitive to MIRAPEX or its ingredients

2. Refer to the insert paper for other contraindication.

• Following patients should be carefully administered.

1. Patient with renal impairment

2. Refer to the insert paper for other precaution.